The PatchMD Berberine Patch is specifically formulated to complement these medications with targeted nutrients that help support metabolism, glucose regulation, fat-burning pathways, and overall wellness
Clinical studies have shown that patients treated with GLP-1 receptor agonists not only experience significant weight loss but also improvements in associated health markers, such as blood pressure and lipid profiles
The following are used to make these patches: Note: The actual GLP-1 agonist drug patches containing semaglutide are still under trial are known to reduce appetite, manage cravings and hunger, and give a feeling of fullness 4
FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023)
They may have watched friends or family members lose significant weight on semaglutide or tirzepatide
Orum Therapeutics is attempting to overcome this challenge through DACs, which use antibody-mediated delivery to selectively target vulnerable cell populations